Background: Diabetic nephropathy (DN) is part of the greatest broadly known diabetic microvascular intricacies inducing around 40% of patients with type 2-diabetes Mellitus (T2DM), Its advancements to end-stage renal disease (ESRD); the primary recognition of DN can be achieved with biomarkers of diabetes. This study evaluates the role of the power of the early biomarker recognition of DN in the T2DM serum. Design and Methods: A case-control study, it included 90-people, and composed from both genders and age range of individual study was (40-69 years); which divided into 3-groups by using the urinary albumin/ creatinine ratio (ACR). Included 60-patients with T2DM without/with proteinuria, which also divided into 2-groups group I, normoalbuminuria (30 mg/g) and group II, microalbuminuria (30–300 mg/g); Addition to 30-persons, healthy control group (30 mg/g), (free from any disease); the assay was applied by turbidimetric/ biochromatic rate. In all groups, β-TP and NGAL which were estimated in serum and both biomarkers having the same methodology by quantitative enzyme immunoassay, (double-antibody sandwich). Results: The serum β-TP and NGAL have significantly higher levels in diabetic patients with microalbuminuria (group II) as parallel with those with normoalbuminuria (group I) and healthy control, nevertheless their levels have no significant variance between group I and healthy control subjects. Conclusions: Results of this suggest that serum β-TP and NGAL in diabetic patients with type 2, can be considered a valuable biomarker for early detection of DN.
展开▼
